KTC
SUPN icon

Kistler-Tiffany Companies’s Supernus Pharmaceuticals SUPN Stock Holding History

Kistler-Tiffany Companies’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-20
Closed – – 686
2016
Q2 		$0 Buy
+20
New +$355 ﹤0.01% 722

Other funds holding SUPN

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Kistler-Tiffany Companies's SUPN Position: Q3 2016 in Review

Kistler-Tiffany Companies sold out of Supernus Pharmaceuticals (SUPN) in Q3 2016, closing a stake of 20 shares.

Kistler-Tiffany Companies first reported a position in SUPN in Q2 2016 and held it in 1 quarter. The position peaked at $0 in Q2 2016. 222 funds tracked by Wall St. Rank hold SUPN as of Q3 2016.

  • Kistler-Tiffany Companies reported no remaining Supernus Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Kistler-Tiffany Companies sold 20 Supernus Pharmaceuticals shares in Q3 2016.
  • Kistler-Tiffany Companies first reported a position in Supernus Pharmaceuticals in Q2 2016 and held it in 1 quarter.
  • Kistler-Tiffany Companies's Supernus Pharmaceuticals position peaked at $0 in Q2 2016.
  • 222 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2016.

Based on Kistler-Tiffany Companies's 13F filing for Q3 2016, filed 8 Nov 2016.